Vaccination against the extra domain-B of fibronectin as a novel tumor therapy

FASEB Journal

Volumn 24, Issue 11, 2010, Pages 4535-4544

  Huijbers, Elisabeth J M ^a   Ringvall, Maria ^a   Femel, Julia ^a   Kalamajski, Sebastian ^a,c   Lukinius, Agneta ^b   Åbrink, Magnus ^a   Hellman, Lars ^a   Olsson, Anna Karin ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Angiogenesis; Extracellular matrix; Immunization; Neovascularization; Therapeutic

Indexed keywords

CANCER VACCINE; EXTRA DOMAIN BETA FIBRONECTIN; FIBRONECTIN; GLUTATHIONE S TRANSFERASE EXTRA DOMAIN BETA; THIOREDOXIN; THIOREDOXIN EXTRA DOMAIN BETA; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTHRITIS; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER SIZE; CONTROLLED STUDY; CRYOPRESERVATION; ELECTRON MICROSCOPE; ELECTRON MICROSCOPY; FIBROSARCOMA; GLIOMA; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; NEUTROPHIL; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR VOLUME; VACCINATION; VACCINE PRODUCTION; WOUND HEALING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; CANCER VACCINES; CELL LINE, TUMOR; FIBRONECTINS; MICE; MICE, INBRED C57BL; MODELS, IMMUNOLOGICAL; MODELS, MOLECULAR; NEOPLASMS; PROTEIN STRUCTURE, TERTIARY;

MUS;

EID: 78649842826     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.10-163022     Document Type: Article

References (31)

1. Hellman, L. (2008) Therapeutic vaccines against IgE-mediated allergies. Expert Rev. Vaccines 7, 193-208
2. Ridolfi, L., Petrini, M., Fiammenghi, L., Riccobon, A., and Ridolfi, R. (2009) Human embryo immune escape mechanisms rediscovered by the tumor. Immunobiology 214, 61-76
3. Hellman, L. (1994) Profound reduction in allergen sensitivity following treatment with a novel allergy vaccine. Eur. J. Immunol. 24, 415-420
4. Vernersson, M., Ledin, A., Johansson, J., and Hellman, L. (2002) Generation of therapeutic antibody responses against IgE through vaccination. FASEB J. 16, 875-877
5. Neri, D., and Bicknell, R. (2005) Tumour vascular targeting. Nat. Rev. Cancer 5, 436-446
6. Zardi, L., Carnemolla, B., Siri, A., Petersen, T. E., Paolella, G., Sebastio, G., and Baralle, F. E. (1987) Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J. 6, 2337-2342
7. Carnemolla, B., Balza, E., Siri, A., Zardi, L., Nicotra, M. R., Bigotti, A., and Natali, P. G. (1989) A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J. Cell Biol. 108, 1139-1148
8. Castellani, P., Viale, G., Dorcaratto, A., Nicolo, G., Kaczmarek, J., Querze, G., and Zardi, L. (1994) The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int. J. Cancer 59, 612-618
9. Astrof, S., and Hynes, R. O. (2009) Fibronectins in vascular morphogenesis. Angiogenesis 12, 165-175
10. Midulla, M., Verma, R., Pignatelli, M., Ritter, M. A., Courtenay-Luck, N. S., and George, A. J. (2000) Source of oncofetal ED-B-containing fibronectin: implications of production by both tumor and endothelial cells. Cancer Res. 60, 164-169
11. Tarli, L., Balza, E., Viti, F., Borsi, L., Castellani, P., Berndorff, D., Dinkelborg, L., Neri, D., and Zardi, L. (1999) A high-affinity human antibody that targets tumoral blood vessels. Blood 94, 192-198
12. Demartis, S., Tarli, L., Borsi, L., Zardi, L., and Neri, D. (2001) Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin. Eur. J. Nucl. Med. 28, 534-539
13. Halin, C., Rondini, S., Nilsson, F., Berndt, A., Kosmehl, H., Zardi, L., and Neri, D. (2002) Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat. Biotechnol. 20, 264-269
14. Schliemann, C., Palumbo, A., Zuberbuhler, K., Villa, A., Kaspar, M., Trachsel, E., Klapper, W., Menssen, H. D., and Neri, D. (2009) Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood 113, 2275-2283
15. Sauer, S., Erba, P. A., Petrini, M., Menrad, A., Giovannoni, L., Grana, C., Hirsch, B., Zardi, L., Paganelli, G., Mariani, G., Neri, D., Durkop, H., and Menssen, H. D. (2009) Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 113, 2265-2274
16. Workman, P., Balmain, A., Hickman, J. A., McNally, N. J., Rohas, A. M., Mitchison, N. A., Pierrepoint, C. G., Raymond, R., Rowlatt, C., Stephens, T. C., and et al. (1988) UKCCCR guidelines for the welfare of animals in experimental neoplasia. Lab. Anim. 22, 195-201
17. Tchougounova, E., Jiang, Y., Brasater, D., Lindberg, N., Kastemar, M., Asplund, A., Westermark, B., and Uhrbom, L. (2009) Sox5 can suppress platelet-derived growth factor B-induced glioma development in Ink4a-deficient mice through induction of acute cellular senescence. Oncogene 28, 1537-1548
18. Magnusson, S. E., Pejler, G., Kleinau, S., and Abrink, M. (2009) Mast cell chymase contributes to the antibody response and the severity of autoimmune arthritis. FASEB J. 23, 875-882
19. Santimaria, M., Moscatelli, G., Viale, G. L., Giovannoni, L., Neri, G., Viti, F., Leprini, A., Borsi, L., Castellani, P., Zardi, L., Neri, D., and Riva, P. (2003) Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin. Cancer Res. 9, 571-579
20. Gundersen, H. J., Bendtsen, T. F., Korbo, L., Marcussen, N., Moller, A., Nielsen, K., Nyengaard, J. R., Pakkenberg, B., Sorensen, F. B., Vesterby, A., and West, M. J. (1988) Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. Apmis 96, 379-394
21. Burton-Wurster, N., Lust, G., and Macleod, J. N. (1997) Cartilage fibronectin isoforms: in search of functions for a special population of matrix glycoproteins. Matrix. Biol. 15, 441-454
22. Peters, J. H., Chen, G. E., and Hynes, R. O. (1996) Fibronectin isoform distribution in the mouse. II. Differential distribution of the alternatively spliced EIIIB, EIIIA, and V segments in the adult mouse. Cell. Adhes. Commun. 4, 127-148
23. Carnemolla, B., Neri, D., Castellani, P., Leprini, A., Neri, G., Pini, A., Winter, G., and Zardi, L. (1996) Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain. Int. J. Cancer 68, 397-405
24. Castellani, P., Borsi, L., Carnemolla, B., Biro, A., Dorcaratto, A., Viale, G. L., Neri, D., and Zardi, L. (2002) Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am. J. Pathol. 161, 1695-1700
25. Ma, Y., HayGlass, K. T., Becker, A. B., Fan, Y., Yang, X., Basu, S., Srinivasan, G., Simons, F. E., Halayko, A. J., and Peng, Z. (2007) Novel recombinant interleukin-13 peptide-based vaccine reduces airway allergic inflammatory responses in mice. Am. J. Respir. Crit. Care. Med. 176, 439-445 (Pubitemid 47358097)
26. Le Buanec, H., Paturance, S., Couillin, I., Schnyder-Candrian, S., Larcier, P., Ryffel, B., Bizzini, B., Bensussan, A., Burny, A., Gallo, R., Zagury, D., and Peltre, G. (2007) Control of allergic reactions in mice by an active anti-murine IL-4 immunization. Vaccine 25, 7206-7216
27. Haller, B. K., Brave, A., Wallgard, E., Roswall, P., Sunkari, V. G., Mattson, U., Hallengard, D., Catrina, S. B., Hellstrom, M., and Pietras, K. (2010) Therapeutic efficacy of a DNA vaccine targeting the endothelial tip cell antigen delta-like ligand 4 in mammary carcinoma. [E-pub ahead of print] Oncogene doi: 10.1038/onc.2010.176
28. Birchler, M. T., Milisavlijevic, D., Pfaltz, M., Neri, D., Odermatt, B., Schmid, S., and Stoeckli, S. J. (2003) Expression of the extra domain B of fibronectin, a marker of angiogenesis, in head and neck tumors. Laryngoscope 113, 1231-1237
29. Hauptmann, S., Zardi, L., Siri, A., Carnemolla, B., Borsi, L., Castellucci, M., Klosterhalfen, B., Hartung, P., Weis, J., Stocker, G., Haubeck, H.-D., and Kirkpatrick, C. J. (1995) Extracellular matrix proteins in colorectal carcinomas. Expression of tenascin and fibronectin isoforms. Lab. Invest. 73, 172-182
30. Kaczmarek, J., Castellani, P., Nicolo, G., Spina, B., Allemanni, G., and Zardi, L. (1994) Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int. J. Cancer 59, 11-16
31. Ringvall, M., Huijbers, E. J., Ahooghalandari, P., Alekseeva, L., Andronova, T., Olsson, A. K., and Hellman, L. (2009) Identification of potent biodegradable adjuvants that efficiently break self-tolerance-a key issue in the development of therapeutic vaccines. Vaccine 28, 48-52